Diuretics

• 

  Subject Areas on Research

  • "Time Is Muscle" in Acute Heart Failure: Critical Concept or Fake News? 
  • A Contemporary Picture of Congestion in Heart Failure: from Dropsy Impression to Multifaceted Reality. 
  • A Systematic Review of Diuretics in the Medical Management of Ménière's Disease. 
  • A combined clinical and biomarker approach to predict diuretic response in acute heart failure. 
  • A major role for the EP4 receptor in regulation of renin. 
  • A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). 
  • A systematic review of the evidence supporting post-operative diuretic use following cardiopulmonary bypass in children with Congenital Heart Disease. 
  • Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. 
  • Acidic stimuli activates two distinct pathways in taste receptor cells from rat fungiform papillae. 
  • Acute Responses to Diuretic Therapy in Extremely Low Gestational Age Newborns: Results from the Prematurity and Respiratory Outcomes Program Cohort Study. 
  • Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. 
  • Acute heart failure in the young: Clinical characteristics and biomarker profiles. 
  • Advanced heart failure: a call to action. 
  • An 8-year-old girl with headache and syncope. 
  • Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome? 
  • Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. 
  • Back to the Future With Intravenous Diuretics: Reinvigorating an Old Treatment Through New Care Settings. 
  • Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 
  • Calcium stone disease: an overview. 
  • Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. 
  • Cardiac function and heart failure. 
  • Chloride transport inhibitors influence recovery from oxygen-glucose deprivation-induced cellular injury in adult hippocampus. 
  • Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. 
  • Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Combating Acute Heart Failure in the Arena: Lessons From the ROPA-DOP Trial. 
  • Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. 
  • Combination of loop diuretics with thiazide-type diuretics in heart failure. 
  • Combined effect of bumetanide and metolazone in normal volunteers. 
  • Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. 
  • Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. 
  • Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. 
  • Congestive heart failure. 
  • Congestive heart failure: Dx and Rx in the elderly. 
  • Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome. 
  • Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. 
  • Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. 
  • Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Death: The Simple Clinical Trial Endpoint. 
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. 
  • Development and validation of the Proxy-Reported Pulmonary Outcomes Scale for premature infants. 
  • Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. 
  • Diagnostic and Therapeutic Challenges. 
  • Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). 
  • Differential regulation of renin and Cox-2 expression in the renal cortex of C57Bl/6 mice. 
  • Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. 
  • Diuretic Treatment in Heart Failure. 
  • Diuretic complications. 
  • Diuretic exposure in premature infants from 1997 to 2011. 
  • Diuretic management in heart failure. 
  • Diuretic resistance predicts mortality in patients with advanced heart failure. 
  • Diuretic response in acute heart failure-an analysis from ASCEND-HF. 
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 
  • Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. 
  • Diuretic strategies in patients with acute decompensated heart failure. 
  • Diuretics and sudden cardiac death. 
  • Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. 
  • Door-to-Furosemide Therapy in the ED: New Quality Metric or Just a Piece of the Puzzle? 
  • Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension. 
  • Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. 
  • Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). 
  • Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. 
  • Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Effects of gender and ethnic group on blood pressure control in the elderly. 
  • Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. 
  • Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys. 
  • Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys. 
  • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. 
  • Electromechanical associations. 
  • Endpoints for diuresis: are we there yet? 
  • Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. 
  • Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries. 
  • Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. 
  • Fluid removal in acute heart failure: diuretics versus devices. 
  • Furosemide and mannitol suppression of epileptic activity in the human brain. 
  • Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. 
  • Heart failure drug treatment. 
  • Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. 
  • Hemoconcentration-guided diuresis in heart failure. 
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hyperlipidemia and transplantation: etiologic factors and therapy. 
  • Hypertension. 
  • Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. 
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. 
  • Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. 
  • Implementation of a diuretic stewardship program in a pediatric cardiovascular intensive care unit to reduce medication expenditures. 
  • Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). 
  • Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. 
  • Initial therapy of hypertension. 
  • Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 
  • Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. 
  • Intensity and focus of heart failure disease management after hospital discharge. 
  • International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. 
  • International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. 
  • Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment? 
  • Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? 
  • Is there a need for medical evaluation and treatment of nephrolithiasis in the "age of lithotripsy"? 
  • Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. 
  • Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. 
  • Long-term treatment of calcium nephrolithiasis with potassium citrate. 
  • Lovastatin and coadministered antihypertensive/cardiovascular agents. 
  • Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. 
  • Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Management of acute decompensated heart failure. 
  • Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Massive pulmonary pseudotumor. 
  • Medical advances in the treatment of congestive heart failure. 
  • MicroRNAs relate to early worsening of renal function in patients with acute heart failure. 
  • Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. 
  • Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure. 
  • My hair is thinning on the top of my head. What treatments are available for hair loss in women? 
  • Nondialytic management of hyperkalemia and pulmonary edema among end-stage renal disease patients: an evaluation of the evidence. 
  • Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. 
  • Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States. 
  • Overview of current noninodilator therapies for acute heart failure syndromes. 
  • Oxaluria--the neglected stepchild of nephrolithiasis? 
  • Participation in weight-related sports is associated with higher use of unhealthful weight-control behaviors and steroid use. 
  • Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. 
  • Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. 
  • Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. 
  • Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. 
  • Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 
  • Pharmacologic treatment of calcium calculi. 
  • Possible protein binding displacement interaction between glibenclamide and metolazone. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants. 
  • Propranolol and depression: a reevaluation based on a pilot clinical trial. 
  • Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. 
  • Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. 
  • Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial. 
  • Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. 
  • Recognizing the Significance of Outpatient Worsening Heart Failure. 
  • Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. 
  • Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. 
  • Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). 
  • Renal calculi: pathogenesis, diagnosis, and medical therapy. 
  • Reply: Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction. 
  • Reply: Efficacy of Subcutaneous vs. Intravenous Administration of Furosemide in Patients With Worsening Heart Failure: The Devil Is in the Details. 
  • Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. 
  • Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy? 
  • Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D. 
  • Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. 
  • Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. 
  • Role of guanylate cyclase modulators in decompensated heart failure. 
  • Role of microsomal prostaglandin E synthase 1 in the kidney. 
  • Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. 
  • Safety of nifedipine in patients with hypertension: a meta-analysis. 
  • Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. 
  • Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). 
  • Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. 
  • Sex-specific acute heart failure phenotypes and outcomes from PROTECT. 
  • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. 
  • Sox6 as a new modulator of renin expression in the kidney. 
  • Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). 
  • Specific binding sites for atrial natriuretic factor in the human kidney. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Dh gene of Drosophila melanogaster encodes a diuretic peptide that acts through cyclic AMP. 
  • The current role of medical treatment of nephrolithiasis: the impact of improved techniques of stone removal. 
  • The effect of furosemide on intravascular volume status and electrolytes in patients receiving mannitol: an intraoperative safety analysis. 
  • The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. 
  • The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The pharmacokinetics of bumetanide in the newborn infant. 
  • Thiazide diuretic agents and the incidence of hip fracture. 
  • Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. 
  • Ultrafiltration in decompensated heart failure with cardiorenal syndrome. 
  • Ultrafiltration in heart failure with cardiorenal syndrome. 
  • Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. 
  • Usefulness of spironolactone in a specialized heart failure clinic. 
  • Vanilloid receptor activation by 2- and 10-microm particles induces responses leading to apoptosis in human airway epithelial cells. 
  • Water and sodium in heart failure: a spotlight on congestion. 
  • Weight perceptions and weight control practices in American Indian and Alaska Native adolescents. A national survey. 
  • What's new in diuretic therapy. 
  • When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF. 
  • When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. 
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery